Avances terapéuticos en el tratamiento del cáncer de ovario: OLAPARIB: primer inhibidor de PARP - page 1

AVANCES TERAPÉUTICOS EN EL TRATAMIENTO DEL CÁNCER DE OVARIO:

OLAPARIB: PRIMER INHIBIDOR DE PARP

Ana Oaknin, MD PhD

Head of Gynecologic Cancer Program. Vall d´Hebron Institute of Oncology( VHIO).

Vall d´Hebron University Hospital.

Barcelona, Spain

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1 2,3,4,5,6,7,8,9,10,11,...33